Clinical trials are the only way to generate the evidence needed to bring new immunotherapy treatments into the care of people living with type 1 diabetes.
Participation in a clinical trial provides the opportunity to access promising new treatments and to be cared for by a highly motivated team of specialists. Connection with the clinical trial community also enables you to receive early notice of new therapeutic developments and new clinical trials.
You can also benefit from the knowledge that your effort in participating in a clinical trial will help others affected by type 1 diabetes, both now and into the future.
IAA trial – Abatacept combined with nasal insulin in recently-diagnosed type 1 diabetes
IAA is a randomised controlled trial testing whether the combination of two safe immune therapies called abatacept and nasal insulin slows down the immune attack on the insulin producing (beta) cells of people with newly-diagnosed type 1 diabetes. If effective, the combination of these two therapies could delay the need for insulin injections. Approximately 60 participants will receive abatacept in combination with either nasal insulin or placebo over a 48-week period. Participants will be required to attend their local trial centre 17 times over two years, with majority of visits lasting less than one hour.
The ATIC network is dedicated to the early detection of markers for type 1 diabetes, called antibodies. Identification of people with antibodies can lead to a better prognosis and management of type 1 diabetes long term. Those with a positive antibody test can also participate in clinical trials aimed at delaying the onset of symptomatic type 1 diabetes. Relative of people with type 1 diabetes aged between 2 and 30, living in Australia and New Zealand can register for a blood test.
IMPACT – IMCY-0098 Proof of Action in Type 1 Diabetes
ATIC researchers are trialling a new medication called IMCY-0098 to see whether it preserves pancreas function by dampening the immune attack on insulin-producing cells that occurs in people with type 1 diabetes. IMCY-0098 is administered as an injection under the skin in 7 doses over a 24-week period. Participants in this study will be required to attend 9 visits at their nearest clinical centre over a 12-month period and two follow-up visits in the second year.
BANDIT – Baricitinib in New Onset Type 1 Diabetes Mellitus
The BANDIT study will determine whether a drug called baricitinib is effective in halting the immune attack on insulin-producing cells that is the ultimate cause of type 1 diabetes. If successful, baricitinib will help people with newly diagnosed type 1 diabetes continue to produce insulin for longer.
Location: Victoria and South Australia Age: 10 – 30 years
Within 100 days of diagnosis with type 1 diabetes